[144] Cellebrite DI Ltd. SEC Filing

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBT) Form 144 shows a proposed sale of 508,790 common shares, with an aggregate market value of $9,366,104.61, to be sold on or about 09/24/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing breaks out how the shares were acquired: 10,373 shares from restricted stock dated 09/17/2025 and 498,417 shares from a stock option exercise on 09/24/2025 paid in cash. It also discloses a recent sale of 6,847 shares on 09/02/2025 for gross proceeds of $112,016.92. The filer attests there is no undisclosed material adverse information.

Positive

• Clear disclosure of the number of shares, acquisition dates, and nature of acquisition (restricted stock and option exercise).
• Broker identified (Morgan Stanley Smith Barney LLC), providing transparency on execution venue.
• Cash payment noted for the option exercise, indicating exercise funding was completed.

Negative

• Significant dollar value of proposed sale: $9,366,104.61, which could increase market supply in the near term.
• Insider selling activity includes a recent sale of 6,847 shares on 09/02/2025, suggesting ongoing disposition.

Insights

Financial Analyst

TL;DR: Insider plans to sell ~508k shares (~$9.37M) shortly after exercising options, increasing free float modestly.

The filing indicates an insider conversion and immediate monetization: 498,417 shares arose from an option exercise paid in cash and are included in the proposed sale. The aggregate size of the proposed sale represents about 0.21% of the reported outstanding shares (508,790 of 244,469,106), which is modest in percentage terms but notable in dollar value. Recent small sale of 6,847 shares for $112,016.92 shows prior disposition activity. For investors, this is a liquidity event by an insider rather than a demonstrated change in company fundamentals; no financial results or operational disclosures are contained in this filing.

Corporate Governance Expert

TL;DR: Filing is a routine Rule 144 notification showing compliance steps for an insider sale following grant/exercise events.

The form documents required disclosures: acquisition dates, nature of acquisition (restricted stock and option exercise), and the broker handling the transaction. The signer certifies absence of undisclosed material adverse information and references Rule 10b5-1 considerations. There are no governance red flags evident in the document itself, but the timing—restricted stock vesting followed by option exercise and a near-term sale—warrants monitoring for any pattern of post-grant selling. No regulatory or litigation matters are disclosed here.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	508790	9366104.61	244469106	09/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2025	Restricted Stock	Issuer			10373	09/17/2025	Not Applicable
Common	09/24/2025	Stock Option Exercise	Issuer			498417	09/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ALIAZAR KEINAN 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Common	09/02/2025	6847	112016.92

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for CLBT disclose about the planned sale?

The filing discloses a proposed sale of 508,790 common shares valued at $9,366,104.61, to be sold on or about 09/24/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.

How were the shares to be sold by the CLBT filer acquired?

The filing shows 10,373 shares from restricted stock dated 09/17/2025 and 498,417 shares from a stock option exercise on 09/24/2025 paid in cash.

Did the filer sell any CLBT shares recently?

Yes, the filer sold 6,847 shares on 09/02/2025 for gross proceeds of $112,016.92.

Which broker will handle the proposed CLBT sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer state there is undisclosed material information about CLBT?

The filer represents by signature that they do not know of any material adverse information